NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100. However, NIAID believes the vaccine developed by its Vaccine Research Center (VRC) is scientifically intriguing and sufficiently different from previously tested HIV vaccines to consider testing it in a smaller, more focused clinical study. Therefore, NIAID will entertain a proposal for an alternative study with one specific goal: to determine if the vaccine regimen significantly lowers viral load—the amount of HIV in the blood of vaccinated individuals who may later become infected with HIV.